China SXT Pharmaceuticals (SXTC) Cash & Equivalents (2018 - 2026)

China SXT Pharmaceuticals (SXTC) has reported Cash & Equivalents for 9 consecutive years, with $28.2 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents rose 55.68% year-over-year to $28.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $28.2 million (up 55.68% YoY) and the FY2026 annual result came in at $28.2 million, up 55.42% from the prior year.
• Cash & Equivalents climbed to $28.2 million in Q1 2026 per SXTC's latest filing, from $21.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for SXTC reached as high as $28.2 million in Q1 2026 and fell as low as $12.1 million in Q1 2024.
• A 5-year average of $18.2 million and a median of $17.4 million in 2023 frame the typical range for Cash & Equivalents.
• Annual changes were most pronounced in 2024 — Cash & Equivalents tumbled 30.46% — and 2026, when it soared 55.68%.
• Year by year, Cash & Equivalents stood at $15.6 million in 2022, then grew by 11.55% to $17.4 million in 2023, then advanced by 6.59% to $18.5 million in 2024, then climbed by 14.33% to $21.2 million in 2025, then surged by 33.12% to $28.2 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $28.2 million, $21.2 million, and $18.1 million for Q1 2026, Q3 2025, and Q1 2025 respectively.